STEM-PD is a two part study with the first being a blinded randomised control trial, and the other being an open label trial.
STEM-PD is a non-invasive neuromodulation device. It is like a headphone that sits on your head, it stimulates the brain (neuromodulation). The aim of the study is that
 to see if the device provides a safe and effective treatment for non-motor symptoms for people with Parkinson’s
 to see if the device improves motor symptoms and subsequently quality of life for people with Parkinson’s.
OPEN FOR RECRUITMENT
The Orchestra Study is a clinical research study for people with early-stage Parkinson’s disease. The aim of the study is to see whether the investigational medication known as UCB0599 can slow the progression of Parkinson’s disease.
In order to do this, the drug UCB0599 has to be compared with a placebo – which looks like the study drug but contains no medicinally active ingredients.
The study enrolls patients with Parkinson’s disease from several countries across North America and Europe. As it is assessing disease and symptom progression over a long period of time, the Orchestra Study can only recruit patients with early-stage Parkinson’s disease who show mild symptoms.
OPEN TO RECRUITMENT
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson’s disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa (L-DOPA) 100 mg as first strategy for the treatment of wearing-off.
The study consists of a one-week screening period, four weeks of open-label treatment and two weeks of post-study follow-up. The total study duration for each patient will be approximately 7 weeks.
OPEN TO RECRUITMENT
This is a study sponsored by UCB (a pharmaceutical company) for their new potential medication, UCB0022. This drug works by working on the target sites in the brain (dopamine receptors) which ultimately increase the dopamine effects in the brain, then reduce patients symptoms. The study is a 18 days stay in a research centre (HMR Parks Royal) where you would be given the drug with doctors and nurses taking care of you. You would have a 3 hour formal screening visit at the site before the study, then after the 18 days of admission, you would need to attend two outpatient follow-up. For finishing the study, you’ll get £3,900 (if additional visits are needed, they will be paid for accordingly to you). A full information sheet can be sent to you if you wish to know more and have interest in the study.
A phase-3 RCT – active-controlled, double-blind, double-dummy, parallel group trial to determine the effect of ND0612 on daily “ON” time without troublesome dyskinesia (defined as the sum of “ON” time without dyskinesia and “ON” time with non-troublesome dyskinesia) using subject-completed “ON/OFF” diary assessments of motor function in subjects with Parkinson’s disease (PD) experiencing motor fluctuations
DUOdopa/Duopa in Patients with Advanced Parkinson’s Disease (PD) – a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE).
A global multicentre single-arm observational study to assess the effectiveness of levodopa/carbidopa intestinal gel treatment on OFF time as reported by advanced PD patients. The study period is split as  baseline,  treatment with PEG-J vistit and titration period of up to 14 days, and  up to 36 months observations.
Phase III trial looking at the use of sublingual apomorphine in patients with advanced Parkinson’s Disease. Sponsor: Sunovion. Currently recruiting.
Phase 3, 4-week, Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure Participants are randomised to ampreloxetine or placebo and will recieve a single, oral daily dose of active or placebo drug for 4 weeks.
A 52-week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects with Parkinson’s disease. This phase 3 open label study is using this new form of LD/CD (ABBV-951) which is a novel form of administering the medication.